Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23329876 | 1.00 | YTHDC1 (0.43) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| SCHEMBL5009994 | 1.00 | YTHDC1 (0.43) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| Hydrochloric Acid SCHEMBL21222660 | 0.99 | YTHDC1 (0.42) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| Hydrochloric Acid SCHEMBL21222657 | 0.99 | YTHDC1 (0.42) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| SCHEMBL23304768 | 0.93 | YTHDC1 (0.39) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| SCHEMBL23329109 | 0.93 | YTHDC1 (0.39) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| SCHEMBL23329107 | 0.92 | KMT2A (0.41) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| SCHEMBL3016886 | 0.87 | OPRM1 (0.39) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| SCHEMBL3031430 | 0.87 | OPRM1 (0.39) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 | |
| SCHEMBL23329406 | 0.87 | SLC6A2 (0.38) | YTHDC1SLC6A2SLC6A4KMT2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431323-A | Heterobicyclic amides as CD38 inhibitors | 贝林格尔·英格海姆国际有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-114423753-B | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-117580829-A | Quinoline and azaquinolines as inhibitors of CD38 | 勃林格英格翰国际有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4284511-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | Boehringer Ingelheim International GmbH (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-20230158024-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-05-25 | — | — | US | disclosed |
| US-20230158024-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-05-25 | — | — | US | disclosed |
| US-20230025807-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-01-26 | — | — | US | disclosed |
| WO-2022165114-A1 | QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| EP-4003980-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | Ribon Therapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| EP-1846395-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025807-A1 | CD38 INHIBITORS | CD38, GLS, IDH2 | YTHDC1 2791/4885SLC6A2 513/4885SLC6A4 1662/4885 |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | YTHDC1 2866/4885SLC6A2 3633/4885SLC6A4 3883/4885 |
| US-20230158024-A1 | CD38 INHIBITORS | CD38, NQO1, NDUFAB1 | YTHDC1 2285/4885SLC6A2 974/4885SLC6A4 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.